Sravani Keerthi Ramisetty

Dr. Sravani Keerthi Ramisetty

City of Hope, Duarte, California, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
RERachel Evans
Rachel Evans
SRSravani Keerthi Ramisetty
Sravani Keerthi Ramisetty
Prakash KulkarniPrakash Kulkarni
Prakash Kulkarni
KWKeith R. Weninger
Keith R. Weninger
Intense study of intrinsically disordered proteins (IDPs) did not begin in earnest until the late 1990s when a few groups, working independently, convinced the community that these ‘weird’ proteins could have important functions. Over the past two decades, it has become clear that IDPs play critical roles in a multitude of biological phenomena with prominent examples including coordination in signaling hubs, enabling gene regulation, and regulating ion channels, just to name a few. One contributing factor that delayed appreciation of IDP functional significance is the experimental difficulty in characterizing their dynamic conformations. The combined application of multiple methods, termed integrative structural biology, has emerged as an essential approach to understanding IDP phenomena. Here, we review some of the recent applications of the integrative structural biology philosophy to study IDPs.

11 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SRSravani Keerthi Ramisetty
Sravani Keerthi Ramisetty
Prakash KulkarniPrakash Kulkarni
Prakash Kulkarni
Supriyo BhattacharyaSupriyo Bhattacharya
Supriyo Bhattacharya
ANArin Nam
Arin Nam
SSSharad S Singhal
Sharad S Singhal
AMATISH MOHANTY
ATISH MOHANTY
Translational research in medicine, defined as the transfer of knowledge and discovery from the basic sciences to the clinic, is typically achieved through interactions between members across scientific disciplines to overcome the traditional silos within the community. Thus, translational medicine underscores ‘Team Medicine’, the partnership between basic science researchers and clinicians focused on addressing a specific goal in medicine. Here, we highlight this concept from a City of Hope perspective. Using cisplatin resistance in non-small cell lung cancer (NSCLC) as a paradigm, we describe how basic research scientists, clinical research scientists, and medical oncologists, in true ‘Team Science’ spirit, addressed cisplatin resistance in NSCLC and identified a previously approved compound that is able to alleviate cisplatin resistance in NSCLC. Furthermore, we discuss how a ‘Team Medicine’ approach can help to elucidate the mechanisms of innate and acquired resistance in NSCLC and develop alternative strategies to overcome drug resistance.

27 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Prakash KulkarniPrakash Kulkarni
Prakash Kulkarni
AMATISH MOHANTY
ATISH MOHANTY
Supriyo BhattacharyaSupriyo Bhattacharya
Supriyo Bhattacharya
SSSharad S Singhal
Sharad S Singhal
LGLinlin Guo
Linlin Guo
Ravi SalgiaRavi Salgia
Ravi Salgia
Drug resistance remains one of the major impediments to treating cancer. Although many patients respond well initially, resistance to therapy typically ensues. Several confounding factors appear to contribute to this challenge. Here, we first discuss some of the challenges associated with drug resistance. We then discuss how a ‘Team Medicine’ approach, involving an interdisciplinary team of basic scientists working together with clinicians, has uncovered new therapeutic strategies. These strategies, referred to as intermittent or ‘adaptive’ therapy, which are based on eco-evolutionary principles, have met with remarkable success in potentially precluding or delaying the emergence of drug resistance in several cancers. Incorporating such treatment strategies into clinical protocols could potentially enhance the precision of delivering personalized medicine to patients. Furthermore, reaching out to patients in the network of hospitals affiliated with leading academic centers could help them benefit from such innovative treatment options. Finally, lowering the dose of the drug and its frequency (because of intermittent rather than continuous therapy) can also have a significant impact on lowering the toxicity and undesirable side effects of the drugs while lowering the financial burden carried by the patient and insurance providers.

Verified
Journal Article
Open access
PDF file
SRSravani Keerthi Ramisetty
Sravani Keerthi Ramisetty
ASAyalur Raghu Subbalakshmi
Ayalur Raghu Subbalakshmi
SPSiddhika Pareek
Siddhika Pareek
TMTamara Mirzapoiazova
Tamara Mirzapoiazova
DDDana Do
Dana Do
Prakash KulkarniPrakash Kulkarni
Prakash Kulkarni
Cancer cells, like all other organisms, are adept at switching their phenotype to adjust to the changes in their environment. Thus, phenotypic plasticity is a quantitative trait that confers a fitness advantage to the cancer cell by altering its phenotype to suit environmental circumstances. Until recently, new traits, especially in cancer, were thought to arise due to genetic factors; however, it is now amply evident that such traits could also emerge non-genetically due to phenotypic plasticity. Furthermore, phenotypic plasticity of cancer cells contributes to phenotypic heterogeneity in the population, which is a major impediment in treating the disease. Finally, plasticity also impacts the group behavior of cancer cells, since competition and cooperation among multiple clonal groups within the population and the interactions they have with the tumor microenvironment also contribute to the evolution of drug resistance. Thus, understanding the mechanisms that cancer cells exploit to tailor their phenotypes at a systems level can aid the development of novel cancer therapeutics and treatment strategies. Here, we present our perspective on a team medicine-based approach to gain a deeper understanding of the phenomenon to develop new therapeutic strategies.

10 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BCBridget Crossman
Bridget Crossman
RHRegan Lisa Harmon
Regan Lisa Harmon
KKKourtney Lynn Kostecki
Kourtney Lynn Kostecki
NMNellie McDaniel
Nellie McDaniel
MIMari Iida
Mari Iida
DWDeric L Wheeler
Deric L Wheeler
Head and neck squamous cell carcinoma (HNSCC) is diagnosed in more than 71,000 patients each year in the United States, with nearly 16,000 associated deaths. One significant hurdle in the treatment of HNSCC is acquired and intrinsic resistance to existing therapeutic agents. Over the past several decades, the University of Wisconsin has formed a multidisciplinary team to move basic scientific discovery along the translational spectrum to impact the lives of HNSCC patients. In this review, we outline key discoveries made throughout the years at the University of Wisconsin to deepen our understanding of therapeutic resistance in HNSCC and how a strong, interdisciplinary team can make significant advances toward improving the lives of these patients by combatting resistance to established therapeutic modalities. We are profoundly grateful to the many scientific teams worldwide whose groundbreaking discoveries, alongside evolving clinical paradigms in head and neck oncology, have been instrumental in making our work possible.

Verified
Journal Article
Open access
PDF file
ASAyalur Raghu Subbalakshmi
Ayalur Raghu Subbalakshmi
SRSravani Keerthi Ramisetty
Sravani Keerthi Ramisetty
AMATISH MOHANTY
ATISH MOHANTY
SPSiddhika Pareek
Siddhika Pareek
DDDana Do
Dana Do
Prakash KulkarniPrakash Kulkarni
Prakash Kulkarni
Epithelial-to-mesenchymal transition (EMT) is a major axis of phenotypic plasticity not only in diseased conditions such as cancer metastasis and fibrosis but also during normal development and wound healing. Yet-another important axis of plasticity with metastatic implications includes the cancer stem cell (CSCs) and non-CSC transitions. However, in both processes, epithelial (E) and mesenchymal (M) phenotypes are not merely binary states. Cancer cells acquire a spectrum of phenotypes with traits, properties, and markers of both E and M phenotypes, giving rise to intermediary hybrid (E/M) phenotypes. E/M cells play an important role in tumor initiation, metastasis, and disease progression in multiple cancers. Furthermore, the hybrid phenotypes also play a major role in causing therapeutic resistance in cancer. Here, we discuss how a systems biology perspective on the problem, which is implicit in the ‘Team Medicine’ approach outlined in the theme of this Special Issue of The Journal of Clinical Medicine and includes an interdisciplinary team of experts, is more likely to shed new light on EMT in cancer and help us to identify novel therapeutics and strategies to target phenotypic plasticity in cancer.